K. Celli-Lebras

发表

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies

Matthew J. Frigault, G. Lucchini, Jackie Chappell, 2020, The Lancet.

Frugal alignment-free identification of FLT3-internal tandem duplications with FiLT3r

H. Dombret, C. Preudhomme, R. Itzykson, 2022, bioRxiv.

Clofarabine Improves Relapse-Free Survival of Acute Myeloid Leukemia in Younger Adults with Micro-Complex Karyotype

H. Dombret, C. Preudhomme, X. Thomas, 2019, Cancers.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

J. Cayuela, H. Dombret, C. Preudhomme, 2014, Haematologica.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Leukemia research.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA

H. Dombret, C. Preudhomme, Aurélie Caillault, 2014, American journal of hematology.

SNP-array lesions in core binding factor acute myeloid leukemia

H. Dombret, G. Leverger, C. Preudhomme, 2018, Oncotarget.

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia patients treated in the ALFA0701 trial.

H. Dombret, C. Preudhomme, X. Thomas, 2019, Blood.

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use

H. Dombret, C. Preudhomme, S. de Botton, 2020, Haematologica.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Blood.

A Personalized Approach to Guide Allogeneic Stem Cell Transplantation in Younger Adults with Acute Myeloid Leukemia.

J. Bourhis, H. Dombret, S. Chevret, 2020, Blood.

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.

J. Bourhis, H. Dombret, C. Preudhomme, 2020, Blood advances.

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

H. Dombret, S. Chevret, C. Preudhomme, 2015 .

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

H. Dombret, S. Chevret, B. Quesnel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

J. Cayuela, H. Dombret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia

J. Soulier, H. Dombret, B. Quesnel, 2017, Leukemia.

Outcome of older patients with acute myeloid leukemia in first relapse

H. Dombret, S. Chevret, B. Quesnel, 2013, American journal of hematology.

Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML, an ALFA study.

H. Dombret, C. Preudhomme, L. Adès, 2021, Blood.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

H. Dombret, C. Preudhomme, X. Thomas, 2018, Haematologica.

Genetic Identification of AML Patients Older than 60 years Achieving Long-term Survival with Intensive Chemotherapy.

H. Dombret, C. Preudhomme, T. Cluzeau, 2021, Blood.

Relative Mitochondrial Priming Predicts Survival in Older AML Patients Treated Intensively

E. Clappier, H. Dombret, A. Plesa, 2022, HemaSphere.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

H. Dombret, S. Chevret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

J. Soulier, E. Clappier, H. Dombret, 2020, Leukemia.

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

H. Dombret, C. Preudhomme, L. Adès, 2019, Blood.

Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study

H. Dombret, C. Preudhomme, C. Gardin, 2021, Blood.

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

H. Dombret, S. Leprêtre, R. Gressin, 2021, Clinical lymphoma, myeloma & leukemia.

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2023, Leukemia.

LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study

H. Dombret, C. Preudhomme, S. de Botton, 2023, Blood advances.

Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group

H. Dombret, C. Preudhomme, T. Cluzeau, 2022, Blood.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

H. Dombret, S. Chevret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Blood.

Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study

C. Preudhomme, R. Itzykson, C. Terré, 2024, Blood cancer journal.